Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 449-459

  Rizzo, Angelamaria ^a   Monteleone, Ivan ^a   Fina, Daniele ^a   Stolfi, Carmine ^a   Caruso, Roberta ^a   Fantini, Massimo Claudio ^a   Franzè, Eleonora ^a   Schwendener, Reto ^b   Pallone, Francesco ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

colitis; Crohn's disease; IL 25; macrophages

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

ALTERNATIVELY ACTIVATED MACROPHAGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LAMINA PROPRIA; MACROPHAGE; MACROPHAGE ACTIVATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PERITONEUM; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, DIFFERENTIATION; ARGINASE; BETA-N-ACETYLHEXOSAMINIDASES; CELL COUNT; COLITIS; GENE EXPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-13; INTERLEUKIN-17; INTERLEUKIN-4; INTESTINAL MUCOSA; LECTINS; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; STATISTICS, NONPARAMETRIC; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID;

EID: 84857355355     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21799     Document Type: Article

References (29)

1. Abraham C, Cho JH,. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
2. Bouma G, Strober W,. The immunological and genetic basis of inflammatory bowel disease. Nat Rev. 2003; 3: 521-533. (Pubitemid 37328672)
3. Strober W, Fuss I, Mannon P,. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007; 117: 514-521. (Pubitemid 46348505)
4. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112: 1169-1178. (Pubitemid 27157528)
5. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157: 1261-1270. (Pubitemid 126449643)
6. Fujino S, Andoch A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003; 52: 65-70. (Pubitemid 36020767)
7. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Iinvest. 2001; 108: 601-609. (Pubitemid 32777740)
8. Caruso R, Sarra M, Stolfi C, et al. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology. 2009; 136: 2270-2279.
9. Angkasekwinai P, Park H, Wang YH, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med. 2007; 204: 1509-1517. (Pubitemid 47048018)
10. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001; 15: 985-995. (Pubitemid 34075378)
11. Owyang AM, Zaph C, Wilson EH, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med. 2006; 203: 843-849.
12. Zaph C, Du Y, Saez SA, et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med. 2008; 205: 2191-2198.
13. Caruso R, Stolfi C, Sarra M, et al. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood. 2009; 113: 3512-3519.
14. Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Bioscience. 2008; 13: 453-461. (Pubitemid 351599757)
15. Gordon S, Martinez FO,. Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32: 593-604.
16. Pesce JT, Ramalingam TR, Mentink-kane MM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathogens. 2009; 5: e1000371.
17. Hunter MM, Wang A, Parhar KS, et al. In vitro-derived alternatively activated macrophages reduce inflammation in mice. Gastroenterology. 2010; 138: 1395-1405.
18. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011; 140: 221-230.
19. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549-555. (Pubitemid 35223554)
20. Wang Y, Wang YP, Zheng G, et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 2007; 72: 290-299. (Pubitemid 47172367)
21. Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med. 1996; 183: 2605-2616. (Pubitemid 26192369)
22. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006; 131: 1786-1798. (Pubitemid 44958514)
23. Stein M, Keshav S, Harris N, et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176: 287-292.
24. Rodriguez-Sosa M, Satoskar AR, Calderòn R, et al. Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infect Immun. 2002; 70: 3656-3664. (Pubitemid 34666004)
25. Herbert RD, Orekov T, Perkins C, et al. IL-10 and TGF-β redundantly protect against severe liver injury and mortality during acute schistosomiasis. J Immunol. 2008; 181: 7214-7220.
26. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995; 182: 1281-1290.
27. Fiorucci S, Mencarelli A, Palazzetti B, et al. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity. 2002; 17: 769-780. (Pubitemid 35477796)
28. Stolfi C, Caruso R, Franzè E, et al. Interleukin-25 fails to activate STAT6 and induce alternatively activated macrophages. Immunology. 2011; 132: 66-77.
29. Pesce J, Kaviratne M, Ramalingam TR, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest. 2006; 116: 2044-2055. (Pubitemid 44033328)